At a glance
- Originator Toa Eiyo
- Class Antiplatelets
- Mechanism of Action Serotonin 2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 31 Oct 2003 Discontinued - Phase-I for Thrombosis in Japan (PO)
- 11 Oct 2002 No development reported - Phase-I for Thrombosis in Japan (PO)
- 23 May 2000 New profile